Stefan Schreiber
Appearances
- DateMay 9, 2023BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
- DateMay 9, 2023BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Presenter
Northwestern Feinberg School of MedicineSpeakers
Icahn School of Medicine at Mount Sinai - DateMay 9, 2023BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Presenter
Western UniversitySpeakers
Barts & The London School of Medicine and Dentistry - DateMay 9, 2023BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Presenter
Speakers
Icahn School of Medicine, Mount SinaiSwedish Medical CenterWestern UniversityKatholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven - DateMay 9, 2023Background: Patients with inflammatory bowel disease (IBD) often modify their diet in attempt to manage their disease and symptoms. In some cases, dietary changes involve excessive restriction, which may place patients at risk for adverse consequences…
Speakers
Presenter
Icahn School of Medicine, Mount Sinai - DateMay 20, 2024Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…
Presenter
Icahn School of Medicine, Mount Sinai - DateMay 21, 2024BACKGROUND: Risankizumab (RZB), a monoclonal antibody targeting interleukin-23 p19, was evaluated for maintenance therapy in patients with moderately to severely active ulcerative colitis (UC) and clinical response to RZB intravenous (IV) induction treatment in a phase 3 double-blind, placebo (PBO)…
Presenter
Speakers
Charité - Universitätsmedizin BerlinMayo Foundation for Medical Education and Research - DateMay 21, 2024BACKGROUND: VTX002 is a novel oral selective sphingosine-1-phosphate-1 (S1P1) receptor modulator in development for the treatment of ulcerative colitis (UC)…
Presenter
Speakers
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
